• Shifting Paradigms in Multiple Myeloma: Future Insights to Practice - Register Now
  • Key Issues in the Treatment of Lymphoma: The Role of CD30 in Diagnosis and Management  - Register Now
  • Contemporary Therapy for HL: Where Are We Now? - Register Now
  • Begin Now
  • Begin CE Activity
  • Earn CME Now
  • View New CE Activity Now
  • New Options, New Hope: Recent Chemotherapeutic Advances in Metastatic Pancreatic Cancer

What's New

Untitled Document
CE Education
Individualizing Therapeutic Options and Achieving Goals in Chronic Lymphocytic Leukemia (CLL)
Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD; Peter Hillmen, MD, FRCP, FRCPath, PhD; Thomas J. Kipps, MD
CE Education
Expert Strategies in Mantle Cell Lymphoma: Age-based Differential Approaches to Induction Therapy
Julie M. Vose, MD, MBA – Chair; John P. Leonard, MD; Brad S. Kahl, MD
CE Education
Evolving Treatment Paradigms in Chronic Lymphocytic Leukemia: Challenging Cases and Expert Strategies
Susan M. O’Brien, MD – Chair; John C. Byrd, MD; Nicole Lamanna, MD
CE Education
Aligning Current Practice in Febrile Neutropenia with Guideline-based Care
James O. Armitage, MD – Moderator; R. Donald Harvey, PharmD, FCCP, BCOP; Gary H. Lyman, MD, MPH, FASCO
FAQ Library
What are the recommended management strategies for patients with low-risk febrile neutropenia?
Christopher R. Flowers, MD

What is the incidence of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP

How do you define chemotherapy-related febrile neutropenia?
R. Donald Harvey, III, PharmD, FCCP, BCOP

What are the risk factors for the development of febrile neutropenia (FN) in patients receiving chemotherapy?
R. Donald Harvey, III, PharmD, FCCP, BCOP